Top Menu

FDA Issues Suicide Warnings on Chantix, Zyban

/By

Patients taking the stop-smoking drugs Chantix and Zyban/Wellbutrin should be closely monitored for symptoms of serious mental illness that could lead to the risk of suicide, according to a new directive from the U.S. Food and Drug Administration (FDA).

The New York Times reported July 2 that FDA officials stressed that patients should not be discouraged from taking the drugs. “Stopping smoking is a goal we should all be working towards,” said FDA official Curtis J. Rosebraugh. “We don't want to scare people off from trying a medication that could help them achieve this goal. You should just be careful.”

FDA announced plans to add a stronger warning to Chantix packaging, and drug maker Glaxo will add the warnings currently on Wellbutrin to Zyban — both formulations of the drug buproprion.

Sales of smoking-cessation drugs have declined in recent years. Chantix, made by Pfizer, controls about 90 percent of the smoking-cessation drug market, with $846 million in annual sales. Still, the drug has fallen short of sales expectations, in part because of prior safety concerns.

No responses yet.

Leave a Reply

Please read our comment policy and guidelines before you submit a comment. Your email address will not be published. Thank you for visiting Drugfree.org


6 + = nine

Disclaimer:
Reproduction in whole or in part of this publication is strictly prohibited without prior consent. Photographic rights remain the property of Join Together and the Partnership for Drug-Free Kids. For reproduction inquiries, please e-mail jointogether@drugfree.org.